Luana Ale Bertoncello Pael

Dr. Luana Ale Bertoncello Pael

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2024 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
CMCamila Dias Machado
Camila Dias Machado
PFPaulo Vitor Farago
Paulo Vitor Farago
CCCaroline de Moura Costa
Caroline de Moura Costa
KFKatyuce Souza Farias
Katyuce Souza Farias
DSDenise Brentan Silva
Denise Brentan Silva
JMJane Manfron
Jane Manfron

10 June 2025 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
LPLuciane Barbosa Pessoa
Luciane Barbosa Pessoa
LALucas Polizzeli Azevedo
Lucas Polizzeli Azevedo
AMAline Aparecida Macedo Marques
Aline Aparecida Macedo Marques
JPJuliane Barbosa Pessoa
Juliane Barbosa Pessoa
LPLuana Ale Bertoncello Pael
Luana Ale Bertoncello Pael
AJArquimedes Gasparotto Junior
Arquimedes Gasparotto Junior

27 August 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MAMaria Medina De Azevedo
Maria Medina De Azevedo
MSMaria Luiza Fidelis da Silva da Silva
Maria Luiza Fidelis da Silva da Silva
GSGabriela Pereira da Silva
Gabriela Pereira da Silva
Joyner David Anaya MirandaJoyner David Anaya Miranda
Joyner David Anaya Miranda
AMAnnye Vitória Moraes
Annye Vitória Moraes
AJArquimedes Gasparotto Junior
Arquimedes Gasparotto Junior
Background: Hypertensive disorders of pregnancy present a major global health challenge. Green nanotechnology offers a strategy to enhance the stability and efficacy of bioactive natural products. This study evaluated gold nanoparticles green-synthesized with Pfaffia glomerata extract (AuNPs-PG) against gestational hypertension and fetal complications in spontaneously hypertensive rats (SHRs). Methods: P. glomerata root extract was characterized by UHPLC-MS/MS. AuNPs-PG were green-synthesized with 2 mmol/L HAuCl4 (1:5 v/v) at 40 °C and characterized by UV-Vis and DLS. Pregnant Wistar-Kyoto and SHRs were divided into naive, negative control (NC), amlodipine (5 mg/kg), and AuNPs-PG groups (0.03, 0.1, and 0.3 mg/kg) treated daily on gestational days 1–18 to evaluate maternal cardiovascular, renal, biochemical, and reproductive outcomes. Results: UHPLC-MS/MS identified 38 compounds. AuNPs-PG showed a plasmon band at 520–550 nm and 88.1 nm hydrodynamic diameter. In SHRs, 0.3 mg/kg AuNPs-PG reduced systolic blood pressure by 18.5% and mean arterial pressure by 15.4%, while mitigating vascular dysfunction by lowering phenylephrine vasoconstriction by 52.7% and boosting acetylcholine vasodilation by 239.3%. Treatment shortened QTc interval by 26.4%, normalized T-wave inversion, and restored renal excretion, increasing urinary volume by 75.0% and sodium by 94.2%. Furthermore, AuNPs-PG elevated placental growth factor by 180.9%, lowered malondialdehyde by 63.5%, and preserved placental histology. Consequently, mean fetal weight increased by 21.6%, implantation index by 50.5%, and offspring-to-mother ratio by 129.6%. Conclusions: AuNPs-PG (0.3 mg/kg) effectively mitigate maternal and fetal complications in gestational hypertension. Gold nanoparticles serve as nanocarriers, whereas surface-adsorbed phytochemicals drive the biological effects.

9 October 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
GSGabriela Pereira da Silva
Gabriela Pereira da Silva
LPLuana Ale Bertoncello Pael
Luana Ale Bertoncello Pael
MSMaria Luiza Fidelis da Silva da Silva
Maria Luiza Fidelis da Silva da Silva
MAMaria Medina De Azevedo
Maria Medina De Azevedo
TSTelma Lélia Gonçalves Schultz
Telma Lélia Gonçalves Schultz
AJArquimedes Gasparotto Junior
Arquimedes Gasparotto Junior
Background/Objectives: Metabolic syndrome (MS) encompasses a cluster of disorders that significantly increase cardiovascular risk. While α-amyrin exhibits antioxidant and anti-inflammatory properties, its poor aqueous solubility and low oral bioavailability hinder its clinical use. This study evaluated the cardioprotective effects of α-amyrin-loaded polymeric nanocapsules (NCαA) in spontaneously hypertensive rats (SHR) with sucrose-induced MS. Methods: First, NCαA was prepared via interfacial deposition of a preformed polymer following organic solvent displacement. The formulation was characterized for particle size, zeta potential, morphology, encapsulation efficiency, and storage stability. Spontaneously hypertensive rats (SHR) received 20% sucrose for 8 weeks and were treated daily by oral gavage for 28 days with NCαA (0.1, 0.3, or 1 mg/kg), unformulated α-amyrin (1 mg/kg), hydrochlorothiazide (25 mg/kg), vehicle, or blank nanocapsules. Cardiovascular, electrocardiographic, echocardiographic, vascular, renal, and biochemical parameters were subsequently assessed. Results: Polymeric NCαA showed spherical and uniform morphology (195.10 ± 1.55 nm; PDI: 0.144; zeta potential: −52.60 mV), 85.85% encapsulation efficiency, efficient sustained release, and 90-day shelf-life stability. In vivo, MS control rats exhibited significant weight gain, hypertension, increased S-wave negative deflection depth, reduced ejection fraction, impaired acetylcholine-mediated vasodilation, depressed serum nitrite, and elevated malondialdehyde. Treatment with NCαA (particularly at 0.3 and 1 mg/kg), unlike unformulated α-amyrin, prevented excessive weight gain, normalized blood pressure, reversed electrophysiological/echocardiographic markers of cardiac overload, restored nitric oxide bioavailability, attenuated lipid peroxidation, and maintained renal hydroelectrolytic balance. Conclusions: Polymeric nanoencapsulation yielded stable nanocapsules with high sustained release, overcoming the biopharmaceutical limitations of α-amyrin. NCαA provides comprehensive cardioprotection against MS-induced damage, representing a promising multi-target strategy for cardiometabolic disorders.